Literature DB >> 30808615

Right-angled vessels in macular telangiectasia type 2.

Simone Tzaridis1, Tjebo Heeren2,3, Clarissa Mai4, Sarah Thiele4, Frank G Holz4, Peter Charbel Issa5, Philipp Herrmann4.   

Abstract

PURPOSE: To evaluate the role of right-angled vessels (RAVs) during disease progression in macular telangiectasia type 2 (MacTel).
METHODS: In this study, 100 eyes of 52 patients and 52 eyes of 26 age-related controls were examined using fundus photography, spectral-domain optical coherence tomography (SD-OCT), OCT angiography (OCT-A) and fundus fluorescein angiography (FFA). Two masked readers graded fundus photographs of patients' eyes into five disease stages according to Gass and Blodi, and evaluated all eyes for the presence of RAVs. If RAVs were present, their course and origin (arterial vs venous) was evaluated with OCT-A and FFA, respectively. Additionally, we looked for morphological correlates of these vessels on SD-OCT scans. Neovascular eyes were analysed for the presence of RAVs and for morphological changes on formation of neovascularisations (NVs).
RESULTS: In OCT-A, RAVs were already detectable in eyes with early stages (1 to 2), could be tracked from superficial to outer retinal layers and were shown to form anastomoses in the outer retina with disease progression. These vessels were of both arterial and venous origin as shown by early phase FFA. Dilated capillaries and RAVs in OCT-A corresponded to hyper-reflective alterations of the outer retina on SD-OCT scans. In 19/19 eyes, NVs were associated with the presence of RAVs, and RAVs were shown to directly connect to neovascular complexes and to undergo morphological changes upon NV formation.
CONCLUSIONS: The results emphasise the role of RAVs during disease progression from an early stage on and demonstrate their involvement in the development of secondary NVs in MacTel. © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  imaging; macula; neovascularisation; retina

Year:  2019        PMID: 30808615     DOI: 10.1136/bjophthalmol-2018-313364

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  7 in total

1.  The Role of Diagnostic Imaging in Macular Telangiectasia Type 2.

Authors:  Brett Zerbinopoulos; Elina Goman-Baskin; Paul B Greenberg; Richard Bryan; Claire Messina
Journal:  Fed Pract       Date:  2021-12-13

2.  The preproliferative stage in type 2 macular telangiectasia (MacTel type 2).

Authors:  Ramesh Venkatesh; Nikitha Gurram Reddy; Pranjal Mishra; Arpitha Pereira; Deepashri Mutalik; Sameeksha Agrawal; Abhishek Bhatt; Naresh Kumar Yadav; Jay Chhablani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-19       Impact factor: 3.117

3.  One-year follow-up of optical coherence tomography angiography microvascular findings: macular telangiectasia type 2 versus tamoxifen retinopathy.

Authors:  Yu Jeong Park; Suhwan Lee; Young Hee Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-05-10       Impact factor: 3.535

4.  Microvascular changes precede visible neurodegeneration in fellow eyes of patients with asymmetric type 2 macular telangiectasia.

Authors:  Kiran Chandran; Anantharaman Giridhar; Mahesh Gopalakrishnan; Sobha Sivaprasad
Journal:  Eye (Lond)       Date:  2021-07-29       Impact factor: 4.456

5.  Venovenous anastomosis in macular telangiectasia type 2: an unusual presentation.

Authors:  Avadhesh Oli; Raja Narayanan
Journal:  BMJ Case Rep       Date:  2020-06-30

6.  Use of OCT Angiography to Diagnose and Manage Atypical Presentations of Macular Telangiectasia Type 2.

Authors:  John Moir; Shivam V Amin; Saira Khanna; Rahul Komati; Lincoln T Shaw; David Dao; Seenu M Hariprasad; Dimitra Skondra
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

7.  Optical coherence tomographic features of macular telangiectasia type 2: Korean Macular Telangiectasia Type 2 Study-Report No. 1.

Authors:  Young Ho Kim; Yoo-Ri Chung; Jaeryung Oh; Seong-Woo Kim; Christopher Seungkyu Lee; Cheolmin Yun; Boram Lee; So Min Ahn; Eun Young Choi; Sungmin Jang; Kihwang Lee
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.